**Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a genetic-**

**based cautionary guide for treatment of COVID-19 symptoms**

Ammar Ali Almarzooq[1]

[1]Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain.

Corresponding author:

Ammar Ali Almarzooq,

Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain.

tel: +973-32171842

email: ammar@galoreconsultancy.com

**ABSTRACT**

Coronavirus disease 2019 (COVID-19), is a rapidly spreading infectious illness that causes a

debilitating respiratory syndrome. While non-steroidal anti-inflammatory drugs (NSAIDs), may be

prescribed for the management of pain and fever, there was early controversy on the use of ibuprofen

for symptomatic treatment of COVID-19. P450 enzyme CYP2C9 are known to be involved in the

metabolism of NSAIDs.  Although no study has been conducted in the setting of population genetics

in patients with COVID-19 yet, there are plausible mechanisms by which genetic determinants may

play a role in adverse drug reactions (ADRs).  In this work, we adjusted expected phenotype

frequencies based on racial demographic models dependent on population ancestry in drug responses

and toxicity events associated with ibuprofen treatment.  A cohort of 101 Jordanian Arab samples

retrospectively were selected and genotyped using Affymetrix DMET Plus Premier Package, within

the context of over 100,000 global subjects in 417 published reports. European populations are 7.2x

more likely to show impaired ibuprofen metabolism than Sub-Saharan populations, and 4.5x more

likely than East Asian ancestry populations. Hence, a proactive assessment of the most likely gene-

drug candidates will lead to more effective treatments and a better understanding of the role of

pharmacogenetics for COVID-19.

**KEYWORDS:** COVID-19, ibuprofen, NSAIDs, pharmacogenetics, population genetics

**Introduction**

The global pandemic of the novel coronavirus disease 2019 (COVID-19) has caused a global

healthcare crisis resulting from high infection and mortality rates[1]. The National Health Commission

of China released key guidelines for the diagnosis and treatment of pneumonitis, and related diseases,

caused by COVID-19[2]. Such guidelines included oxygen therapy, mechanical ventilation and drug

therapy, as well as provided recommendations for simultaneous drug treatments in extreme cases.  For

suspected or confirmed cases of COVID-19, requiring urgent care for conditions such as fever and/or

sore throat, pharmacological management may require antibiotics and/or analgesics, an alternative[2].

Specifically, non-steroidal anti-inflammatory drugs (NSAIDs) e.g. ibuprofen, may be prescribed for

the management of pain and fever. However, uncertainty related to infection etiology and efficacy,

and emerging concerns related to the use of common NSAIDs, have presented additional challenges

in the treatment of COVID-19. Fang and colleagues at the beginning of the pandemic hypothesized a

possible deleterious role of ACE2-stimulating drugs and ibuprofen on the course of SARS-CoV-2

infected patients[3]. The increase of ACE2 expression may lead to a potential rise of SARS-CoV-2 viral

load and consequently to a more severe disease course. Therefore, the authors concluded their

commentary discouraging the use of these drugs in the setting of COVID-19. This plausible

mechanism together with the above-reported evidences of ibuprofen, led the National Agency for the

Safety of Medicines and Health Products (ANSM) of France to release a warning, asking whether

patients showing symptoms of COVID-19 should use paracetamol rather than ibuprofen[4]. This

warning was echoed by the British Medical Journal[5-7], causing an 80% drop in ibuprofen prescriptions

in France[8]. The UK Medicines and Healthcare products Regulatory Agency (MHRA) reported that, in

the absence of clear evidence, patients should be advised to take paracetamol to treat the symptoms of

COVID-19, unless paracetamol is not suitable for them[9]. However, the World Health Organization

(WHO), after initially advising against the use of ibuprofen for COVID-19, quickly retracted the

public[10]. Indeed, the scientific debate on ibuprofen use for COVID-19 continues[10-13]. Abu Esba and

colleagues prospectively recruited 503 adults in Saudi Arabia with confirmed SARS-CoV2 infection

of whom 40 (8%) used ibuprofen during the infection, 17 (3.4%) were assumed to have used other

NSAIDs, and 96 (19%) were chronically treated with NSAIDs before and during the infection.

Neither the acute nor the chronic use of NSAIDs resulted in increased mortality or severe COVID-

19[14]. Also, Kragholm and colleagues reported the data of a retrospective, Danish-based cohort study,

including 4002 adults with COVID-19 of whom 264 (6.6%) were treated with ibuprofen[15]. Again, no

significant association between ibuprofen and severe COVID-19 was found. Finally, Rinott and

colleagues retrospectively evaluated the use of ibuprofen versus paracetamol during the course of

SARS-CoV2 infection in Israel across 403 adult patients, confirming that ibuprofen was not

associated with severe COVID-19[16]. However, currently no study has been conducted in the setting of

population genetics.

Genetic factors are one of the major contributors to individual or ethnic differences in drug

therapeutic efficacy and toxicity[17, 18]. Consequently, host genetics and demography associated with

COVID-19 are crucial aspects of infection and prognosis. Thus, integral medication dosing might

need to be altered based on a patient's genetic information[19, 20]. There are several gene variants that

alter how an individual metabolizes and processes ibuprofen, potentially increasing the risk of

undesirable ADRs. The cytochrome P450 enzyme CYP2C9, facilitates metabolism of several

NSAIDs, including ibuprofen, and *CYP2C9* allele frequencies have been shown to vary substantially

across diverse ethnic groups[21, 22].

In March 2020, the Clinical Pharmacogenetics Implementation Consortium (CPIC) published

a pharmacogenetic guideline on NSAIDs, with specific therapeutic recommendations based on

*CYP2C9* phenotype[23]. The phenotype was derived from an activity score, obtained by the sum of two

individual allele scores. Recent meta-analysis of *CYP2C9* alleles and ibuprofen concentrations using

the Pharmacogenomics Knowledge Base (PharmGKB), showed strong correlations between the

CYP2C9*2 allele (p.R144C; rs1799853) and *CYP2C9*3* allele (*p.I359L; rs1057910*) with plasma

levels of ibuprofen[24-28]. Based on these results, PharmGKB assigned the highest level of evidence

(level 1A) to these associations, indicating these biomarkers were extensively studied and validated in

clinical practice.

However, the goal of this study was to demonstrate that current pharmacogenomics databases

can be leveraged to enhance the identification of a gene alleles, and to determine population

differences in associated drug response/toxicity events. Results from this work have wide ranging

impacts on the targeted treatment of COVID-19 patients across broad geographic ranges and ethnic

backgrounds, thereby facilitating the drug development processes and help with prescribing

therapeutics more safely.

**RESULTS**

*Selection and analysis of CYP2C9 Variations*

Eighteen *CYP2C9* variants across 101 Jordanian individuals of Arab descent associated with reduced

enzyme function were selected (Table 1 & Table S1). The defective allele *2 (rs1799853)* was the

most abundant variant (0.094), followed by allele *3* (rs1057910) (0.084). In addition, two rare

variants, *c.1425A>T (rs1057911)* and *50196C>T (rs2017319)*, were also detected. These two SNPs

had frequencies of less than 0.005. *CYP2C9 *2* and *3* together accounted for 17.8% of the allele

frequency and about 32.7% of the reduced or non-functional genotype/phenotype associations. The

four genotype frequencies *CYP2C9 *1/*1*, *1/*2*, *1/*3* and *2/*3* were 0.673, 0.158, 0.139 and 0.03,

respectively. Moreover, the genotype frequencies showed no deviation from HWE (p□>□0.05; Table

2).

Significant D' values were observed spanning the entire genomic region, following LD

measurements for pairs of SNPs distributed across the 52-kb region.  Most allele pairs of significant

D' values were observed spanning the entire genomic region, following LD measurements for pairs of

SNPs distributed across the 52-kb region.  Most allele pairs of *CYP2C9* had a D′ value equal to 1.0

(indicating complete LD), whereas, r2 values across the same region, show a LD block between the

*7 allele (rs67807361)* at exon 1 and the *14* allele (*rs72558189*) at exon 3. A clear LD block was

also observed between *CYP2C9*3 (rs1057910)* at exon 3 and between c.1425A>T (*rs1057911*) at

exon 9, crossing an approximately 8-kb region (Figure 1A and Table S2).  The experimental group

*rs67807361* was significantly different from the other sampled populations (p=4.9x10-22; Table S3).

However, the nucleotide BLAT search showed that the DNA sequence obtained from the flanking

region of this SNP (124bp) had 100% sequence identity with the *CYP2C19* gene at the region of

10:94762716-94762839 (Figure 1B). Therefore, this variant was excluded from the analyses since the

individual probes in the MIP assay only bind to a genomic footprint of ~40bp.  Thus, the homologous

sequences would likely result in false-positive or false-negative variant calls[29].

*Genetic structure of CYP2C9 across populations*

The two leading principal components from the 13 variants shared between the Jordanian Arab

population and the 22 global populations from the 1000 Genomes Project Phase III (1kG-p3) dataset

(Figure 2A), captured 60.63% and 21.38% of the variance respectively, showing a well-defined

separation between Jordanian Arabs and AFR, EAS, and SAS super populations. Jordanian Arabs had

a close affinity with EUR (comprised of GBR, FIN, TSI, CEPH, and IBS), and validated by pairwise

Fst analyses (Table S4). The lowest level of differentiation was observed between the Jordanian Arab

population and GBR (Fst=5.97 x 10-3), followed by IBS (Fst=6.39 x 10-3), and FIN (Fst=6.69 x 10-

3), whereas the greatest divergence was observed with GWD (Fst=8.54 x 10-2).

Lack of genomic data for additional ethnic groups in the 1000 Genomes Project such as

Middle Eastern populations (ESN), can reduce robustness and potentially result in biased geographic-

based genomic analysis.  Therefore, a secondary analysis was performed to include under-represented

Arab populations.  The two leading principal components shared between the Jordanian Arab

population, and the 18 global reports including ESN for *1*, *2* (*rs1799853*) and *3* (*rs1057910*);

(Table S5) captured 98.35% and 1.62% of the variance, respectively, suggesting a well-defined

genetic separation between Jordanian Arabs and AFR and EAS populations (Figure 2B). In addition,

defined clusters of EUR and ESN populations were found, which were further validated using

pairwise Fst analyses (Table S6). The lowest level of differentiation was observed between the

Jordanian Arab population and Saudi Arabian population (Fst=7.4 x10-4), followed by Italian

(Fst=1.62 x 10-3) and Turkish populations (Fst=1.8 x 10-3), whereas the greatest divergence was

observed with the Korean population (Fst=1.13 x 10-1).

*Pharmacogenetic analyses by biogeographic grouping system*

Across the nine biogeographical groups, 27% of subjects were of East Asian origin, followed by

Europeans (26%), South Central Asians (13%), Near Easterns (12%), Americans (7%), Latinos (6%),

African Americans/Afro-Caribbeans (4%), Sub-Saharan Africans (4%), and Oceanians (1%) (Table

3).  Distinct differences were found among these populations, with direct impacts on ibuprofen

clinical outcomes (Figure 3B). *The CYP2C9 *2* (*rs1799853*) and *3* (*rs1057910*) allele frequencies

were significantly higher in the Central/South Asian origin (0.224), followed by Near Easterns

(0.212), Europeans (0.203), Jordanian Arabs (0.178), and Latinos (0.116), indicating a decreased

metabolism and clearance of ibuprofen as compared to Americans (0.064), Oceanians (0.045), East

Asians (0.04), African Americans/Afro-Caribbeans (0.036) and Sub-Saharan Africans (0.024, Table

S7). These significant variant alleles and genotypes were classified as PharmGKB Level 1A evidence

with reduced enzyme function, and therefore are associated with recommended changes to ibuprofen

dosing[22]. Interpretation of the translation into specific dosing guidelines for individual ibuprofen-

diplotype pairs[23] showed that Central/South Asian, Near Eastern, and European populations are 7.9x

to 5.9x more likely to show impaired CYP2C9 metabolism than African populations (Sub-Saharan

and African American/Afro-Caribbean populations, respectively), and 4.9x more likely than East

Asian populations (Table S7).

Interestingly, a large number of generally less common alleles were also identified based on

this approach (Table S7). Allele *9* (*rs2256871*) was significantly over-represented in Sub-Saharan

Africans (0.13), but was not detected in other global populations (Figure 3A). Alleles *5*

(*rs28371686*), *6* (*rs9332131*), *8* (*rs7900194*) and *11* (*rs28371685*) were significantly over-

represented in African populations (Sub-Saharan African and African Americans/Afro-Caribbean)

and under-represented in other populations. East Asian populations over-represented alleles *42*

(*rs12414460*) and *55* (*42620C>A*).

**DISCUSSION**

Although no direct evidence of pharmacogenomics data in patients with COVID-19 was available at

the time of writing this manuscript, there are plausible mechanisms by which genetic determinants

may play a role in adverse drug responses. While NSAIDs, including ibuprofen, may be prescribed

for the management of pain and fever[2], controversy arose on the use of ibuprofen due to the

possibility of a worse COVID-19 prognosis[3-9]. Ibuprofen may offer symptomatic relief, and could

provide healthcare professionals additional time to deliver customized care. Although this strategy is

not always reliable since individuals may respond differently to similar treatments[22, 23]. In this work,

several genetic markers were analyzed across diverse ethnic backgrounds to identify population

differences in drug responses and toxicity events associated with ibuprofen treatment. Results from

this study showed that pharmacogenomics studies can be leveraged to enhance the understanding of

adverse reactions to the treatment of COVID-19 symptoms and support advancement of drug

development pipelines.

MDS and Fst analyses showed that the Jordanian Arab population clustered with multiple

regions within European and Near Eastern. These results validated that the current Jordanian

population today falls into two main groups: one sharing more genetic characteristics with modern-

day Europeans and Central Asians, and the other with closer genetic affinities to Arabia[30]. In addition,

our analyses are in agreement with recent studies using large-scale genomics that indicated three

major genetic events related to Levant populations. During the late neolithic, gene pools across

Anatolia and the Southern Caucasus mixed, resulting in an admixture cline[31]. The second event

occurred during the Early Bronze Age, where Northern Levant populations, a region flanked by the

Middle East and Europe, experienced gene flow in a process that likely involved a yet to-be-sampled

neighboring population from Mesopotamia[31]. The most recent event for the modern Levant was

largely determined by subsequent repopulations and mass movements associated with multiple

cultural changes within the last two millennia. This appeared to have facilitated and maintained

admixture between culturally different populations[32]. In general, the Jordanian population was not

significantly different from their Levantine neighbours, and fit consistently into a Middle East-

Anatolia-Balkan-Caucasus geographic and genetic continuum[33].

On the other hand, correlation between *CYP2C9* genotypes and plasma levels of ibuprofen

including level 1 evidence biomarkers with clinical pharmacogenetic guidelines[22]. These biomarkers

were extensively studied for years and are already validated in clinical practice; a pharmacogenetic

test prior to drug prescription is warranted. Mapped frequencies of these alleles showed that

Central/South Asian, Near Eastern, and European populations were 7.9x more likely to show impaired

*CYP2C9* metabolism than Sub-Saharan populations, and 4.9x more likely than East Asian ancestry

populations (Table S7). Inference that a higher proportion of East Asian and African ancestry

populations have normal ibuprofen metabolism, and therefore are less susceptible to complications for

ibuprofen-based treatment. Figure 4 shows genotype frequencies of global populations of *CYP2C9\*2*

and *\*3* for more than 100,000 subjects within 412 reports[23].

These findings are in agreement with several earlier European reports of potential harm with

ibuprofen usage in patients with COVID-19 symptoms[4-9]. However, while the scientific debate

whether to use or not ibuprofen in the course of COVID-19 continues[10-13], three recent studies have

recently been published with no significant association between ibuprofen prescription claims and

severe COVID-19 in three countries, Saudi Arabia, Denmark and Israel, respectively[14-16]. These

studies have several limitations. First, they were observational or retrospective studies; no causal

conclusion can be reached, and recall-bias is a concern[14, 16]. Second, as those studies were conducted

at an early stage of the pandemic outbreak, screening strategies in the beginning may have introduced

selection bias relative to strategies at a later period[14-16], such as, the policy of the Israeli Ministry of

Health was to test only those individuals with symptoms that are suggestive of COVID-19. As a

result, they have no information about ibuprofen in asymptomatic carriers, and whether antipyretics

can influence their clinical course[16]. Third, the main analysis of these studies compared NSAID users

with non-NSAID users, but confounding indicators may have influenced the results[14], whereas

ibuprofen users were defined based on prescription fills and information on whether or how many

ibuprofen pills the patients actually took is not available[15]. Ibuprofen also can be purchased as an

over-the-counter drug, they cannot exclude potential misclassification of ibuprofen exposure, as

patients in the non-ibuprofen group may have used over-the-counter ibuprofen[15]. Lastly, their sample

size was not sufficient to allow multivariable analyses[14, 16].

However, the purpose of this study is not to confirm or deny the association between

ibuprofen prescription claims and severe COVID-19. Alternatively, our simulation is based upon

expected phenotype frequencies instead of directly assaying patient biospecimens, these phenotype

frequencies are previously well-described, and are already validated in clinical practice[22, 23]. The

adjusted expected phenotype frequencies based on the racial demographics of our cohort and expected

population phenotype frequencies are dependent on population ancestry[34].

Our analysis also revealed that other variants, such as, rs1057911 marker was found to be in

LD with the variant of *CYP2C9\*3* (*rs1057910*; Figure 1A, Table S2), which is consistent with the

recently published PharmVar change adding *c.1425A>T* (*rs1057911*) to the *\*3* haplotype definition[35].

Further analysis indicated that the array probe used for genotyping may not able to bind specifically

with the target SNPs, due to non-specific binding to another genomic region. Awareness of

problematic regions is critical during test design and reporting to guide decisions regarding exclusion

of regions and/or whether alternative assays must be used. This is particularly the case for

*CYP2C9\*7_5080C>A(L19I)* (*rs67807361*), where both statistical and genetic tests revealed a

homologous sequence that may result in false positive or false negative variant calls.

A well-designed gene detection panel is important to fully characterize patient genotypes

which relate to the drug effects. Although precision medicine should be considered in COVID-19

treatment, there are still many challenges to face. Firstly, a suitable strategy for treatment of COVID-

19 through integrating pharmacogenomics data is still lacking. Secondly, the best treatment regime

can be optimized for each individual patient, and both the efficacy and the safety can be guaranteed.

Existing *CYP2C9* genotype results may provide the potential benefit of identifying populations who

are at an increased risk of experiencing ADRs or therapeutic failure. This work demonstrates the

capability and application of large-scale pharmacogenomics studies to elucidate genetic variation

effects on treatment efficacy in COVID-19 patients. Ultimately, the implementation of

pharmacogenetics in clinical settings is necessary as it leads to more efficient and cost-effective

treatments.

**METHODS**

*Sample collection*

This study retrospectively included 101 unrelated Jordanian participants, of which 56 were male and

45 were female. After signed informed consent, a 3mL venous blood sample was collected in EDTA

from each participant at the Princess Haya Biotechnology Centre between May 2010 and December

2011. Blood samples were stored at 4°C until DNA extraction.  The Institutional Review Board (IRB)

of the Jordan University of Science and Technology approved this study on 4/7/2013 under

registration number 67/2/2013, and performed in accordance with the principles enshrined in the

Declaration of Helsinki.

*DNA extraction and genotyping*

Genomic DNA was extracted from each blood sample using the QIAamp DNA Micro Kit (Qiagen,

Hilden, Germany) according to the manufacturer's instructions. The quality of the purified DNA was

determined using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA

USA).

Genotyping was accomplished using the Affymetrix DMET (Drug Metabolizing Enzymes

and Transporters) Plus Premier microarray assay (Santa Clara, CA, USA) to test for drug metabolism

associations. The DMET array contains 1,936 drug metabolism markers consisting of 1,931 single

nucleotide polymorphisms (SNPs) and five copy number variations (CNVs) in 225 genes. These

genetic variants were multiplex genotyped using molecular inversion probe (MIP) technology[29]. The

profiles for the genotyping call rates and concordance comparisons, were generated by the DMET

console software v1.3 (Thermo Fisher Scientific, Inc., Waltham, MA, USA), based on the Bayesian

robust linear model with Mahalanobis (BRLMM) distance classifier algorithm[36, 37]. Genotypes were

determined for each SNP site and reported as homozygous wild-type, heterozygous, homozygous

variant, and 'no call' in the case of a lack of genotype call. SNPs with a call rate of less than 99%

were excluded from subsequent analyses. Statistical and genetic analyses were performed for

selection and validation using Microsoft Excel and SPSS v16. Linkage disequilibrium (LD) analysis

was performed to identify non-random SNP associations between populations. LD was in

concordance with all worldwide-distributed 1kG-p3 populations[38]. The genotype and allele

frequencies were calculated and tested using the chi-square ($\chi^2$) test and the Hardy–Weinberg

equilibrium formula ($p > 0.05$) (Figure 5).

*Selection of CYP2C9 variants*

LD analysis was performed using the LDlink tool to generate D' and $r^2$ values[39], and a matrix was

generated for visualization. These allele frequencies were compared to 139 different CPIC reports

from European and Near Eastern population groups (Table S8). The statistical comparison of allele

frequencies on experimental data and reference populations were performed by Pearson's $\chi^2$ test with

Bonferroni correction and the negative logarithm of the adjusted significance values [-log10

(adj.p.val)] using the R statistical package v3.6.2 with ggplot2 and visualized using Rstudio v1.3.1056

(Boston, MA). The assembled DNA flanking sequence for each of the SNP loci was also subjected to

BLAT[40] to determine the specificity of the array's probes matched to the target sequence set. A probe

alignment was considered to be specific if 40 consecutive base pairs of the probe were fully aligned

with the target sequence[29]. In order to detect the homologous sequences, which likely result in false-

positive or false-negative variant calls, sequence similarity searches were performed using the

Ensembl BLAST/BLAT search programs with default parameters.

*Population structure analyses*

To identify cryptic relatedness from the genomic data, principal component analysis (PCA)

was performed using the base R function "prcomp" within the R software package and

multidimensional scaling (MDS) plots were generated from the PCA results using ggfortify and

ggplot2[41]. Cryptic population structure was inferred using *CYP2C9* SNP data to identify the ancestral

relatedness between the Jordanian Arab population and three defined datasets: 1,810 individuals from

22 populations from the 1000 Genomes Project Phase III (1kG-p3) dataset, excluding admixed

populations (Table S9); 3,413 individuals from 18 global reports (Table S5); and 31,880 individuals

from 118 reports from the European  (EUR) and Near Eastern (NEA) populations from the CPIC

updated report in March 2020 (Table S10).

Fixation Index (Fst) was used to quantify population differentiation from genetic structure

using SNP allele frequencies. The R package "BEDASSLE" function was used to assess genetic

similarity between ethnic populations by generating pairwise Fst values (0 indicates no divergence, 1

indicates complete separation) between the Jordanian Arab population and the other populations listed

above[41].

*Defined population datasets for structure analyses*

Allele counts for defined populations were obtained from three sources, ethnic defined

populations by the 1000 Genomes Project Phase III (1kG-p3) dataset[38], consisting of 1,810

individuals from 22 populations within four defined ancestral groups (Table S9). The

admixed populations were excluded to simplify the ethnic identification analyses.

1.   African (AFR): Americans of African Ancestry in SW, USA (ASW), Esan in Nigeria

(ESN), Gambian in Western Divisions in the Gambia (GWD), Mende in Sierra Leone

(MSL), Luhya in Webuye, Kenya (LWK), Yoruba in Ibadan, Nigeria (YRI) and

African Caribbeans in Barbados (ACB).

2.   European (EUR): Utah Residents (CEPH) with Northern and Western European

Ancestry (CEU), Finnish in Finland (FIN), British in England and Scotland (GBR),

Iberian Population in Spain (IBS) and Toscani in Italia (TSI).

3.   East Asian (EAS): Han Chinese in Beijing, China (CHB), Chinese Dai in

Xishuangbanna, China (CDX), Southern Han Chinese (CHS), Japanese in Tokyo,

Japan (JPT) and Kinh in Ho Chi Minh City, Vietnam (KHV).

4.   South Asian (SAS): Bengali from Bangladesh (BEB), Indian Telugu from the UK

(ITU), Punjabi from Lahore, Pakistan (PJL), Tamil from the UK (STU) and Gujarati

Indian from Houston, Texas (GIH).

Two more higher-resolution groups of populations consisting of 3,413 individuals from 18

global reports were analyzed (Table S5). The findings were subsequently validated by

increasing the coverage of this structure analysis to include more populations from the CPIC

group across two geographically-defined groups: European (EUR) and Near Eastern (NEA).

The genotypic data of individuals from 118 reports consisting of 31,880 individuals (Table

S10), were downloaded from the CPIC updated report in March 2020 (Figure 5B).

***Biogeographic grouping system for Pharmacogenetic analyses***

To standardize the reporting of ibuprofen susceptibility to develop complications by *CYP2C9*

variability, nine groups consisting of seven geographically-defined groups (American,

Central/South Asian, East Asian, European, Near Eastern, Oceanian, and Sub-Saharan

African) and two admixed groups (African American/Afro-Caribbean and Latino) are

presented in Figure 5C. These nine groups were defined by global autosomal genetic

structure and based on data from large-scale sequencing initiatives[34], are used to illustrate the

broad diversity of global allele frequencies in this study[22, 23, 34, 42, 43, 44]. Furthermore, this

biogeographic grouping system meets a key need in pharmacogenetic research by enabling

consistent communication of the scale of variability in global allele frequencies and is now

used by PharmGKB and CPIC[22, 23, 34]. The genotypic data of individuals from 412 global

populations were downloaded from the CPIC updated report in March 2020.

1.    American (AME):  The American genetic ancestry group includes populations from

both North and South America with ancestors predating European colonization,

including American Indian, Alaska Native, First Nations, Inuit, and Métis in Canada,

and Indigenous peoples of Central and South America.

2.    Central/South Asian (SAS):  The Central and South Asian genetic ancestry group

includes populations from Pakistan, Sri Lanka, Bangladesh, India, and ranges from

Afghanistan to the western border of China.

3.    East Asian (EAS):  The East Asian genetic ancestry group includes populations from

Japan, Korea, and China, and stretches from mainland Southeast Asia through the

islands of Southeast Asia. In addition, it includes portions of central Asia and Russia

east of the Ural Mountains.

4.    European (EUR):  The European genetic ancestry group includes populations of

primarily European descent, including European Americans. We define the European

region as extending west from the Ural Mountains and south to the Turkish and

Bulgarian border.

5. Near Eastern (NEA): The Near Eastern genetic ancestry group encompasses

populations from northern Africa, the Middle East, and the Caucasus. It includes

Turkey and African nations north of the Saharan Desert.

6. Oceanian (OCE): The Oceanian genetic ancestry group includes pre-colonial

populations of the Pacific Islands, including Hawaii, Australia, and Papua New

Guinea.

7. Sub-Saharan African (SSA): The Sub-Saharan African genetic ancestry group

includes individuals from all regions in Sub-Saharan Africa, including Madagascar[8].

8. African American/Afro-Caribbean (AAC): Individuals in the African American/Afro-

Caribbean genetic ancestry group reflect the extensive admixture between African,

European, and Indigenous ancestries and, as such, display a unique genetic profile

compared to individuals from each of those lineages alone. Examples within this

cluster include the Coriell Institute's African Caribbean in Barbados (ACB)

population and the African Americans from the Southwest US (ASW) population[9] and

individuals from Jamaica and the US Virgin Islands.

9. Latino (LAT): The Latino genetic ancestry group is not defined by an exclusive

geographic region, but includes individuals of Mestizo descent, individuals from Latin

America, and self-identified Latino individuals in the United States. Like the African

American/Afro-Caribbean group, the admixture in this population creates a unique

genetic pattern compared to any of the discrete geographic regions, with individuals

reflecting mixed native and indigenous American, European, and African ancestry.

*Pharmacogenetic analyses*

The frequencies of the 13 actionable pharmacogenomics biomarkers were assessed cumulatively for

the Jordanian Arabs against nine biogeographical groups, consisting of 101,407 individuals from 412

global populations[23]. These nine groups were defined by global autosomal genetic structure and based

on data from large-scale sequencing initiatives[34] and are used to illustrate the broad diversity of global

allele frequencies in this study. Furthermore, this biogeographic grouping system meets a key need in

pharmacogenetics research by enabling consistent communication of the scale of variability in global

allele frequencies and are now used by PharmGKB and CPIC[22].

The total frequency of two SNPs with a Level 1A for the Jordanian Arab population within

nine geographically-defined groups were mapped for global impact visualization of allele frequency

on ibuprofen response (Table 3, Figure 5). Inferred frequency for CYP2C9*1 was excluded from our

biogeographical analyses as no population studies have tested for all known variant alleles, and *1*

was not genotyped directly in many studies[23].

429                                                    **References**

430     [1.]     Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N*

431              *Engl J Med.* **382**, 727-733 (2020).

432     [2.]     Lin, L. & Li, T. S. Interpretation of "Guidelines for the Diagnosis and Treatment of

433              Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial

434              Version 5)". *Zhonghua Yi Xue Za Zhi.* **100**, 805-807 (2020).

435     [3.]     Fang, L., Karakiulakis, G., & Roth, M. Are patients with hypertension and diabetes

436              mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory

437              Medicine. **8**, e21. https://doi.org/10.1016/S2213-2600(20)30116-8 (2020).

438     [4.]     ANSM.  COVID-19: the ANSM takes measures to promote the proper use of

439              paracetamol updated on 17/03/2020. 2020. https://ansm.sante.fr/S-informer/Points-d-

440              information-Points-d-information/COVID-19-l-ANSM-prend-des-mesures-pour-

441              favoriser-le-bon-usage-du-paracetamol (2020).

442     [5.]     Little, P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. **368**, m1185

443              (2020).

444     [6.]     Day, M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors

445              and scientists. BMJ. **368**, m1086 (2020).

446     [7.]     Day, M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ. **368**,

447              m1168 (2020)

448     [8.]      ANSM.  COVID-19: Use of medicines in cities during the Covid-19 epidemic:

449              update after five weeks of confinement - Information point updated on 05/04/2020.

450              https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-

451              information/Usage-des-medicaments-en-ville-durant-l-epidemie-de-Covid-19-point-

452              de-situation-apres-cinq-semaines-de-confinement-Point-d-information (2020).

453     [9.]     Medicines and Healthcare products Regulatory Agency. Ibuprofen use and

454               Coronavirus (COVID-19). https://www.gov.uk/government/news/ibuprofen-use-and-

455               covid19coronavirus (2020).

456     [10.]     Moore, N., Carleton, B., Blin, P., Bosco-Levy, P., & Droz, C. Does Ibuprofen Worsen

457               COVID-19? Drug Safety. **43**(7), 611–614 (2020).

458     [11.]     Vosu, J. *et al*. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs

459               increased in COVID-19? J Paediatr Child Health. **56**, 1645–6 (2020).

460     [12.]     Kutti Sridharan, G. *et al*. COVID-19 and avoiding ibuprofen. How good is the

461               evidence? Am J Ther. **27**, e400–2 (2020).

462     [13.]     Sodhi, M. & Etminan, M. Safety of ibuprofen in patients with COVID-19: causal or

463               confounded? Chest, **158**. 55–6 (2020).

464     [14.]     Abu Esba, L. C. *et al*.  Ibuprofen and NSAID use in COVID-19 infected patients is not

465               associated with worse outcomes: a prospective cohort study. Infect Dis Ther. **2**, 1–16

466               (2020).

467     [15.]     Kragholm, K. *et al*. Association Between Prescribed Ibuprofen and Severe COVID-19

468               Infection: A Nationwide Register-Based Cohort Study. Clin Transl Sci. **13**. 1103–

469               1107 (2020).

470     [16.]     Rinott, E., Kozer, E., Shapira, Y., Bar-Haim, A. & Youngster, I. Ibuprofen use and

471               clinical outcomes in COVID-19 patients. Clin Microbiol Infect. **26**, 1259.e5–7.7

472               (2020)

473     [17.]     Gray, J. A. The shift to personalised and population medicine. *Lancet*. **382**, 200-201

474               (2013).

475     [18.]     Peterson, J. F. *et al.* Building evidence and measuring clinical outcomes for genomic

476               medicine. *Lancet*. **394**, 604-610 (2019).

477     [19.]     Burchard, E. G. *et al*. The importance of race and ethnic background in biomedical

478               research and clinical practice. *N Engl J Med*. **348**, 1170-1175 (2003).

479     [20.]     Gemmati, D. & Tisato, V. Genetic Hypothesis and Pharmacogenetics Side of Renin-

480               Angiotensin-System in COVID-19. *Genes (Basel)*. **11**, 1044 (2020).

481      [21.]      Ramamoorthy, A., Pacanowski, M. A., Bull, J. & Zhang, L. Racial/ethnic differences

482                   in drug disposition and response: review of recently approved drugs. *Clin Pharmacol*

483                   *Ther*. **97**, 263-273 (2015).

484      [22.]      Whirl-Carrillo, M. *et al*. Pharmacogenomics knowledge for personalized medicine.

485                   *Clin Pharmacol Ther*. **92**, 414-417 (2012).

486      [23.]      Theken, K. N. *et al*. Clinical Pharmacogenetics Implementation Consortium Guideline

487                   (CPIC) for *CYP2C9* and Nonsteroidal Anti-Inflammatory Drugs. *Clin Pharmacol*

488                   *Ther*. **108**, 191-200 (2020).

489      [24.]      Garcia-Martin, E., Martinez, C., Tabares, B., Frias, J. & Agundez, J. A. Interindividual

490                   variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450

491                   2C8 and 2C9 amino acid polymorphisms. *Clin Pharmacol Ther*. **76,** 119-127 (2004).

492      [25.]      Karazniewicz-Lada, M., Luczak, M. & Glowka, F. Pharmacokinetic studies of

493                   enantiomers of ibuprofen and its chiral metabolites in humans with different variants

494                   of genes coding *CYP2C8* and *CYP2C9* isoenzymes. *Xenobiotica*. **39**, 476-485 (2009).

495      [26.]      Kirchheiner, J. *et al*. Enantiospecific effects of cytochrome P450 2C9 amino acid

496                   variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1

497                   and 2. *Clin Pharmacol Ther*. **72**, 62-75 (2002).

498      [27.]      López-Rodríguez, R. *et al*. Influence of *CYP2C8* and *CYP2C9* polymorphisms on

499                   pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms

500                   of ibuprofen in healthy volunteers. *Pharmacol Res*. **58**, 77-84 (2008).

501      [28.]      Ochoa, D. *et al*. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the

502                   pharmacokinetics of ibuprofen enantiomers. *Pharmacogenomics*. **16:** 939-948 (2015).

503      [29.]      Wang, Y., Cottman, M. & Schiffman, J. D. Molecular inversion probes: a novel

504                   microarray technology and its application in cancer research. *Cancer Genet*. **205**, 341-

505                   355 (2012).

506      [30.]      Haber, M. *et al*. Genome-wide diversity in the levant reveals recent structuring by

507                   culture. *PLoS Genet*. **9**, e1003316 (2013).

508    [31.]    Skourtanioti, E. *et al*. Genomic History of Neolithic to Bronze Age Anatolia, Northern

509             Levant, and Southern Caucasus. *Cell*. **181**, 1158-1175 (2020).

510    [32.]    Scozzari, R. *et al*. Human Y-chromosome variation in the western Mediterranean area:

511             implications for the peopling of the region. *Hum Immunol*. **62**, 871-884 (2001).

512    [33.]    Flores, C. *et al*. Isolates in a corridor of migrations: a high-resolution analysis of Y-

513             chromosome variation in Jordan. *J Hum Genet*. **50**, 435-441 (2005).

514    [34.]    Huddart, R. *et al*. Standardized Biogeographic Grouping System for Annotating

515             Populations in Pharmacogenetic Research. *Clin Pharmacol Ther*. **105**, 1256-1262

516             (2019).

517    [35.]    Gaedigk, A. *et al*. The Pharmacogene Variation (PharmVar) Consortium:

518             Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.

519             *Clin Pharmacol Ther*. **103**, 399-401 (2018).

520    [36.]    Rabbee, N. & Speed, T. P. A genotype calling algorithm for affymetrix SNP arrays.

521             *Bioinformatics*. **22**, 7-12 (2006).

522    [37.]    Sissung, T. M., English, B. C., Venzon, D., Figg, W. D. & Deeken, J. F. Clinical

523             pharmacology and pharmacogenetics in a genomics era: the DMET platform.

524             *Pharmacogenomics*. **11**, 89-103 (2010).

525    [38.]    1000 Genomes Project Consortium., *et al*. A global reference for human genetic

526             variation. *Nature*. **526**, 68-74 (2015).

527    [39.]    Machiela, M. J. & Chanock, S. J. LD link: a web-based application for exploring

528             population-specific haplotype structure and linking correlated alleles of possible

529             functional variants. *Bioinformatics*. **31**, 3555-3557 (2015).

530    [40.]    Kent, W. J. BLAT--the BLAST-like alignment tool. *Genome Res*. **12**, 656-664 (2002).

531    [41.]    R Core Team. R: A language and environment for statistical computing. R Foundation

532             for Statistical Computing. https://www.r-project.org (2013).

533    [42.]    Elhaik, E. *et al*. Geographic population structure analysis of worldwide human

534             populations infers their biogeographical origins. *Nat Commun*. **5**, 3513 (2014).

535     [43.]     Jakobsson, M. *et al*. Genotype, haplotype and copy-number variation in
536               worldwide human populations. *Nature*. **451**, 998-1003 (2008).
537     [44.]     Li, J. Z. *et al*. Worldwide human relationships inferred from genome-wide
538               patterns of variation. *Science*. **319**, 1100-1104 (2008).

**ACKNOWLEDGEMENTS**

**AUTHORS' CONTRIBUTIONS**

AA conceived the research study, performed all the analyses reported and wrote the manuscript.

**CONSENT FOR PUBLICATION**

Consent for publication of the data obtained in this study was retrospectively approved, following de-
identifying information of individuals.

**COMPETING INTERESTS**

The author declares that there is no conflict of interest.

**DATA AVAILABILITY**

The datasets generated during the current study are included in the supplementary files. Publicly

available repositories used in the analyses were previously published under PMID: 32189324 and

downloaded from

https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, and

https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_Diplotype_Phenotype_Table.xlsx.

**ETHICS DECLARATIONS**

Signed informed consent was obtained from all participants recruited for this study under the ethical

approval from University Review Committee for Research on Humans at Jordan University of

Science and Technology (JUST) registered under [67/2/2013] on 4/7/2013, and performed in

accordance with the principles enshrined in the Declaration of Helsinki.

**FIGURE LEGENDS**

Figure 1: *CYP2C9* genetic interpretation in the context of Linkage Disequilibrium (LD) and high

homology sequence. **a.** LD (D' and $r^2$) between 13 single nucleotide polymorphisms (SNPs) in the

*CYP2C9* gene. **b.** Statistical comparison of allele frequencies on experimental data and reference

populations. Color intensity indicates a more significant difference between the given experimental

data and the population.

Figure 2: Population structure analysis of the *CYP2C9 *1*, *2* and *3* alleles. **a.** MDS plot of the 14

variants shared between the Jordanian Arab population and 22 global populations from the 1000

Genomes Project Phase III (1kG-p3) dataset. **b.** MDS plot of the Jordanian Arab population and 18

public worldwide populations. **c.** MDS plot of the Jordanian Arab population and 118 populations

from the Near Eastern (ESN) and European (EUR) groups.

Figure 3: Biogeographical groups and pharmacogenetic analyses for CYP2C9 and ibuprofen

associations. **a.** Frequencies of 13 actionable pharmacogenomics (PGx) alleles and phenotypes

assessed cumulatively for the Jordanian Arab population against the nine biogeographical groups. **b.**

Mapping of the total allele and phenotype frequency of the CYP2C9 alleles *2* and *3*.

Figure 4: Global frequency map of variability in of *CYP2C9* level A alleles and impact on ibuprofen

response. Phenotype prevalence shown for global populations of *CYP2C9*2* and *3*.

Figure 5. Flow chart depicting various steps involved in variant selection, analysis, and annotation. **a.**

Selection of CYP2C9 variations by several statistical and genetic analyses. **b.** Structure analysis by

multidimensional scaling (MDS) plots and fixation Index (Fst) was used to quantify population

differentiation. **c.** Finally, the findings were adapted with nine geographically-defined groups

(>100,000 subjects, 412 reports) in order to estimate genotype-predicted phenotype status across

world populations.

**TABLES**

Table 1. Details of the 18 allele frequencies of *CYP2C9* gene (*NG_008385.1*; *NP_000762.2*)

| SNP | *CYP2C9* Allele | Marker Call Rate | Minor Allele Frequency |
|---|---|---|---|
| g.8633C>T; p.(Arg144Cys) | *2 | 100 | 0.094 |
| g.47639A>C; p.(Ile359Leu) | *3 | 99 | 0.084 |
| g.47640T>C; p.(Ile359Thr) | *4 | 99 | 0 |
| g.47644C>G; p.(Asp360Glu) | *5 | 100 | 0 |
| g.15626delA; p.(Lys273fs) | *6 | 100 | 0 |
| g.5080C>A; p.(Leu19Ile) | *7 | 99 | 0.198 |
| g.15560A>G; p.(His251Arg) | *9 | 100 | 0 |
| g.15623A>G; p.(Glu272Gly) | *10 | 100 | 0 |
| g.47567C>T; p.(Arg335Trp) | *11 | 100 | 0 |
| g.55363C>T; p.(Pro489Ser) | *12 | 100 | 0 |
| g.8301T>C; p.(Leu90Pro) | *13 | 100 | 0 |
| g.8577G>A; p.(Arg125His) | *14 | 100 | 0 |
| g.14125C>A; p.(Ser162Ter) | *15 | 100 | 0 |
| g.38522A>G; p.(Thr299Ala) | *16 | 100 | 0 |
| g.8556_8565delAGAAATGGAA; p.(Lys118fs) | *25 | 100 | 0 |

| | | | |
|---|---|---|---|
| g.55221C>T; p.(Ala441=) | NA | 99 | 0.045 |
| g.47637A>G; p.(Tyr358Cys) | NA | 100 | 0 |
| g.55323A>T; p.(Gly475=) | NA | 100 | 0.045 |

Table 2. Distribution of CYP2C9 alleles and genotypes in Jordanian Arabs (NG_008385.1; NP_000762.2).

| Allele | Variant | Substitution | Allele Count | Allelic Frequency | Genotype | Genotypic Frequency | Observed Genotypes | Expected Genotypes | $\chi^2$ | $p$-value |
|---|---|---|---|---|---|---|---|---|---|---|
| *2 | g.8633C>T; p.(Arg144Cys) | C | 183 | 0.91 | CC | 0.81 | 82 | 82.89 | 1.1 | 0.58 |
| | | | | | CT | 0.19 | 19 | 17.21 | | |
| | | T | 19 | 0.09 | TT | 0.00 | 0 | 0.89 | | |
| *3 | g.47639A>C; p.(Ile359Leu) | A | 185 | 0.92 | AA | 0.83 | 84 | 84.72 | 0.9 | 0.65 |
| | | | | | AC | 0.17 | 17 | 15.57 | | |
| | | C | 17 | 0.08 | CC | 0.00 | 0 | 0.00 | | |

Table 3. Sample size accumulated per biogeographical group

| Population Group | Subjects Genotyped (n) |
|---|---|
| African-American/Afro-Caribbean | 4,277 |
| American | 6,791 |
| Central/South Asian | 13,519 |
| East Asian | 26,906 |
| European | 26,739 |

| | |
|---|---|
| Latino | 6,352 |
| Near Eastern | 11,821 |
| Oceanian | 1,132 |
| Sub-Saharan Africa | 3,870 |
| Total | 101,407 |

**A. CYP2C Core Alleles**

Legend (left): *2, *3, *5, *6, *8, *9, *11, *42, *55, Others

Legend (right): Abnormal/Priority/High Risk, Normal, Unknown

Left chart (% Allele), top to bottom: Oceanian, East Asian, American, African American/Afro-Caribbean, Latino, Jordanian*, European, Near Eastern, Central/South Asian, Sub-Saharan African

Right chart (% Phenotype), top to bottom: Oceanian, East Asian, American, African American/Afro-Caribbean, Latino, Sub-Saharan African, Jordanian Arabs*, European, Near Eastern, Central/South Asian

**B. Ibuprofen Level 1A**

Legend (left): *2, *3

Legend (right): Abnormal/Priority/High Risk, Normal, Unknown

Left chart (% Allele), top to bottom: Sub-Saharan African, African American/Afro-Caribbean, East Asian, Oceanian, American, Latino, Jordanian Arabs*, European, Near Eastern, Central/South Asian

Right chart (% Phenotype), top to bottom: Sub-Saharan African, African American/Afro-Caribbean, East Asian, Oceanian, American, Latino, Jordanian Arabs*, European, Near Eastern, Central/South Asian

**A. Selection**

**101 unrelated Jordanian participants**
**1931 DMET SNPs**

Selection of CYP2C9 variants
18 SNPs

Quality Control: Call rate >99%,
BLAT and Variant Allele Frequency (VAF) < 0.05

A total of 17 SNPs were selected

**B. Structure Analyses**

Structure Analyses

Relatedness with the
1000 Genomes Project Phase III (ikG-p3)
(>1,800 subjects, 22 populations, 13 SNPs)

Relatedness with
higher-resolution population
(>3,400 subjects, 18 populations, three alleles)

Relatedness with the CPIC
(>31,800 subjects, 118 European and
Near East reports, two alleles)

**C. Pharmacogenetic Analyses**

CPIC Biogeographical
Grouping System
(>100,000 subjects, 412 reports)

CPIC Genotypes
13 core alleles

CPIC Genotypes
PharmGKB (level 1A Metabolism/PK)
Two alleles (CYP2C9 *2 and *3)

**Risk Mapping and
Recommendations**

PharmGKB Clinical Annotations
for CYP2C9-ibuprofen